Downloads: 61 | Views: 181
Research Paper | Microbiology | India | Volume 9 Issue 11, November 2020
To Determine the Seroprevalance of Hepatitis B Surface Antigen (HBsAg) and ANTI-HCV Antibodies in Patients Undergoing Haemodialysis
Krishna Kant Sharma [2] | Rahul Soni [2] | Dr. Sweta Gupta
Abstract: Hepatitis B and C is globally one of the most common and severe infectious diseases that leads to significant morbidity and mortality. As such chronic kidney disease is an immune-deficient state, hence blood-borne viral infection particularly HBV and HCV are an important cause of morbidity and mortality of patients treated by haemodialysis. Patients who have undergone haemodialysis for end-stage renal failure are at a higher risk for infections. Aim of the study was to determine the seroprevalence of hepatitis B surface antigen (HBsAg) and Anti-HCV antibodies in patients undergoing Haemodialysis. Serological test for Hepatitis B & Anti-HCV was done by immuno-chromatographic HBsAg and Anti-HCV kit or by CLIA. Immunodiagnostic System. Prevalence of HCV (50.7 %) was slightly higher than that of HBsAg (49.23 %) out the positive cases (65/695) in the Hemodialysis patient. Among the 65 patients, majority i. e.75 % HBsAg and 69 % Anti-HCV reactive were those who underwent dialysis <50 times. We concluded that HCV was more prevalent than that of HBsAg in Hemodialysis patient more studies must be conducted for further research.
Keywords: HBsAg, Anti-HCV, Haemodialysis
Edition: Volume 9 Issue 11, November 2020,
Pages: 674 - 676